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Summary
T cell priming to exogenous antigens reflects regu-
lated antigen processing in dendritic cells, subse-
quent homing to lymph nodes, sustained interactions
between T cells and antigen-bearing dendritic cells,
and, ultimately, selective T cell activation and differ-
entiation. In this study, we test the hypothesis that an
intrinsic property of the class II:peptide complex is
a key determinant that dictates the specificity of an
emerging CD4 T cell response. We found that immu-
nodominant peptides possess extremely long half-
lives with class II molecules (t1/2 > 150 hr), whereas
cryptic peptides displayed half-lives of less than 10
hr. Furthermore, and most importantly, by using a
peptide shuttle vector and four independent antigens,
we demonstrate a direct, causative relationship be-
tween the half-life of peptide epitopes and their immu-
nogenicity in vivo. Taken collectively, our results sug-
gest the half-life of class II:peptide complexes is the
primary parameter that dictates the ultimate hierarchy
of the elicited T cell response.
Introduction
The evolution of a primary CD4 T cell response reflects
sequential events in antigen presentation, dendritic cell
homing, and T cell activation and differentiation. Ulti-
mately in this process, CD4 and CD8 T cells respond to
a very limited subset of peptides within complex pro-
tein antigens. These peptides have been called immu-
nodominant. The focused response to a limited set of
peptides within complex proteins reveals a consider-
able selective pressure on an emerging T cell response.
Previous studies investigating the selectivity of CD4
T cell responses have uncovered several factors that
can influence the specificity of T cells including antigen
processing and presentation, T cell precursor frequency,
and T cell competition (reviewed in Blum et al., 1997;
Kedl et al., 2003; Manoury et al., 2002; Medd and Chain,
2000; Sant et al., 2005; Sercarz et al., 1993). Historically,*Correspondence: andrea_sant@urmc.rochester.eduprocessing of native antigen and subsequent presenta-
tion by APCs has been thought to be one of the major
factors influencing the specificity of T cells. Endosomal
proteolytic processing has the potential to either posi-
tively or negatively affect immunogenicity. The assem-
bly of class II:peptide complexes is another potential
site of regulation. Assembly can be influenced by inter-
peptide competition for binding class II molecules,
modulation by DM, or “epitope capture” by peptides
adjacent to the test peptide. The frequency of peptide-
specific T cells can also influence immunodominance
and, in particular, negative selection can delete CD4 T
cells specific for immunodominant peptides within self-
antigens. Finally, competition between T cells for inter-
action with APCs is a well-documented phenomenon in
the CD8 T cell response and has been proposed to ex-
tend to CD4 T cell responses.
The preceding studies suggested that many complex
events converge to influence the selective specificity of
CD4 T cells during primary immune responses, and the
relative contribution of any of these parameters could
influence immunogenicity. However, our earlier studies
demonstrated that DM expression singularly enhanced
presentation of immunodominant epitopes while antag-
onizing presentation of cryptic peptides (Nanda and
Sant, 2000). This finding suggested that an intrinsic
property of the class II:peptide complex itself might be
the most important parameter in determining immuno-
dominance. In the present study, we test the hypothesis
that in general, an intrinsic feature of class II:peptide
complexes primarily determines the differential priming
and expansion of epitope-specific CD4 T cells. Collec-
tively, our studies revealed that the spontaneous kinetic
stability of class II:peptide molecules is the principal
determinant of the immunogenicity of peptide specifi-
cities within the CD4 T cell response to antigen.
Results
Kinetic Stability Correlates with Immunodominance
To begin these studies, we assembled a set of pre-
viously identified cryptic and immunodominant epi-
topes and characterized their relative affinity for class
II molecules. We utilized I-Ad-restricted epitopes from
divergent origins, including sperm whale myoglobin
(SWM), hen-egg lysozyme (HEL), chicken ovalbumin
(OVA), and L. major (LACK) (Mougneau et al., 1995;
Sercarz et al., 1993). The diversity of these epitopes
with regard to processing and structure provided the
opportunity to isolate a biochemical characteristic that
determined in vivo immunodominance. We evaluated
the potential of both peptide competition and peptide
dissociation assays to distinguish these epitopes. Both
assays have been used to determine the relative
strength of class II:peptide interactions (Kasson et al.,
2000; McFarland et al., 1999a; Sette et al., 1989). Pep-
tide competition assays judge the ability of the test
peptide to inhibit formation of complexes between a
labeled, standardized peptide with class II molecules,
Immunity
30i
whereas dissociation assays directly measure the ki-
netic stability of interaction between the test peptide l
pand class II molecules after the complexes have been
assembled. H
bTo perform binding studies with I-Ad, we produced
and purified soluble class II molecules (Chaves et al., c
A2005). For dissociation assays, we monitored the half-
life of preloaded class II I-Ad peptide complexes bound r
twith fluorescently labeled peptide in vitro at endosomal
pH 5.3 and 37°C. Dissociation was found to fit a single d
pexponential curve with a square correlation coefficient
r2 > 0.99 from which the t1/2 could be determined. Strik- h
(ingly, the dissociation curves from Figure 1A and thec
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Figure 1. Comparison between Peptide Dissociation and Peptide t
Competition
(A) The half-life was calculated from the exponential equation fitted Dto the fluorescence decay curve as a function of the incubation
Wtime and was described as the time required to dissociate the 50%
cof the FITC peptide initially bound to sI-Ad.
(B) The percentage of inhibition of binding of 1 M N-terminal FITC- w
HA(126–138) to sI-Ad by the unlabeled competitor peptide was t
plotted against the concentration of unlabeled inhibitory peptide. p
Data are represented as a Hill Plot (Hill, 1910) and are the average
cof two independent experiments. Error bars represent the range
wobtained in independent experiments.
It1/2 values (Table 1) revealed that immunodominant andryptic epitopes segregated at opposite ends of a very
road kinetic stability spectrum. The immunodominant
pitopes LACK (156–173) (t1/2 = 170 hr), SWM (102–
18); (t1/2 = 260 hr), and OVA (273–288); (t1/2 = 160 hr)
ll displayed long half-lives of 150 hr or greater. In con-
rast, the cryptic epitopes HEL (11–25); (t1/2 = 6 hr) and
EL (20–35); (t1/2 = 4 hr) both displayed very short half-
ives. Collectively, our results suggest that kinetic sta-
ility in class II:peptide complexes may be a critical
haracteristic that determines immunogenicity of a
eptide during an immune response.
In contrast to the results involving kinetic stability
easurements, cryptic and immunodominant peptides
isplayed no consistent groupings when assayed by
ompetition (Figure 1B). For example, the classically
efined cryptic HEL (11–25) peptide competed well
ith HA (126–138) for binding to I-Ad, whereas the simi-
arly cryptic HEL (20–35) peptide competed poorly with
A (126–138) for binding to I-Ad, with a predicted IC50 >
00 M. Also, HA (126–138), LACK (156–173), and OVA
273–288) clustered together, even though their potency
n immunodominance assays are clearly distinct. Col-
ectively, the studies with these unrelated antigens re-
ealed that under the conditions used in our experi-
ents, dissociation rates of peptides from class II
olecules dramatically segregated immunodominant
rom cryptic peptides. We therefore used this parame-
er for the remainder of our experiments. In analyses of
any peptides whose dissociation rates differ by seven
rders of magnitude, McConnell’s group (Kasson et al.,
000) reported that the association rates among these
eptides were essentially the same. This indicates that
easurements of dissociation rates of peptides from
lass II molecules provide a good measure of relative
ffinities. Therefore, in general, values for “affinity” and
dissociation rates” will agree with each other. We do,
owever, continue to generally use the terms “kinetic
tability” and “off-rates” in this paper because that is
he parameter that we vary and measure in our studies.
erivation of Peptide Kinetic Stability Variants
e wished to extend the correlative findings between
lass II:peptide half-lives and immunogenicity to test
hether we could show a causative relationship be-
ween these two parameters. To address this, we sought
eptide variants that possessed increased or de-
reased kinetic stability with I-Ad and then investigated
hether changing the kinetic stability of a given class
I:peptide complex caused a corresponding change in
ts immunogenicity in vivo.
To arrive at generalizable conclusions, three unre-
ated peptides were chosen: the influenza HA (126–138)
eptide, the LACK (156–173) peptide from L. major, and
EL (11–25), each of which offered unique biological or
iochemical properties. The HA (126–138) peptide was
hosen because the crystal structure of HA (126–138):I-
d has been solved (Scott et al., 1998), providing the
egister for the peptide bound to I-Ad. A second advan-
age of the HA (126–138) peptide is its intermediate
issociation rate (t1/2 = 26 hr), which provided an op-
ortunity to investigate the biological properties of both
igher and lower stability variants with I-Ad. The LACK
156–173) peptide from L. major was selected because
it is a prototypical immunodominant epitope from a
Kinetic Stability Controls Immunodominance
31Table 1. Kinetic Stability of Wild-Type and Variant Peptide Epitopes in Association with I-Ad
Peptide SEQUENCE (Putative Register)a t1/2 (h)
1 4 6 9 pH 5.3 I-Ad Relative Position
Myo (102–118) wt K Y L E F I S E A I I H V L H S R 260 na
Lack (156–173) wt I C F S P S L E H P I V V S G S W D 170 na
OVA (273–288) wt M E E R K I K V Y L P R M K M E 160 na
HA (126–138) wt H N T N G V T A A C S H E 26 na
CLIP (85–99) wt K P V S Q M R M A T P L L M R 7 na
HEL (11–25) wt A M K R H G L D N Y R G Y S L 6 na
HEL (20–35) wt* Y R G Y S L G N W V C A A K F E 4 na
HA (126–138) T128M H N M N G V T A A S S H E 165 P1
HA (126–138) T128V H N V N G V T A A S S H E 85 P1
HA (126–138) T128Q H N Q N G V T A A S S H E 63 ± 3 P1
HA (126–138) C135S H N T N G V T A A S S H E 26 P8
HA (126–138) wt H N T N G V T A A C S H E 26 na
HA (126–138) TV,ST H N V N G V T A A S T H E 9 P1, P9
HA (126–138) T128G H N G N G V T A A S S H E 1 P1
HA (126–138) V131A H N T N G A T A A S S H E 0.9 P4
HEL(11–25) RQ,NA,GS A M K Q H G L D A Y R S Y S L 33 P1, P6, P9
HEL (11–25) RQ,GS A M K Q H G L D N Y R S Y S L 11 P1, P9
HEL (11–25) wt A M K R H G L D N Y R G Y S L 6 na
Lack (161–173) wt S L E H P I V V S G S W D 200 na
Lack (161–173) I166A S L E H P A V V S G S W D 2 P4
OVA (327–339) K H A A H A E I N E A G R 0.3 na
OVA (327–339) AI,IV K H A A H I E V N E A G R 87 P4, P6
Half-lives of peptide:I-Ad complexes were calculated from the exponential equation fitted to the fluorescence decay curve as a function of
the incubation time and described as the time required to dissociate the 50% of the FITC peptide initially bound to sI-Ad. Putative pocket
residues for peptides are indicated in bold, and the mutations at pocket residues that modulate kinetic stability are indicated by italics.
a Indicates the binding register for HEL (20–35) is unknown. Cys 135 in HA (126–138) is necessary for T cell activation (not shown), but does
not affect stability in association with I-Ad. Lys 327 in OVA (327–339) was substituted for Val to eliminate alternate register binding. Data is
representative of at least two independent experiments.model protozoan infection (Mougneau et al., 1995;
Reiner et al., 1993). This epitope has been found to
have a high number of T cell precursors (Milon et al.,
1986; Stetson et al., 2002), a property that offered the
opportunity to determine whether reducing kinetic sta-
bility of class II:peptide complexes would be sufficient
to overcome precursor frequency advantages. The HEL
(11–25) peptide is a prototypic cryptic peptide (Moudgil
et al., 1997) and thus provided an opportunity to re-
verse apparent sequestration of a peptide from an im-
mune response solely by stabilizing the interaction of
the peptide with class II molecules.
Initial experiments tested the ability of candidate
variant peptides to maintain T cell stimulatory capacity
when tested with antigen-specific T cell hybridomas.
Peptide variants that passed this initial screen were
evaluated for dissociation kinetics. HA (126–138) vari-
ants included substitutions at P1, P4, or P9 pocket resi-
dues. T cells responded to most HA (126–138) variant
peptides in vitro when presented by I-Ad-expressing
cells (Figure 2A and data not shown). Compared to
wild-type (wt) HA (126–138) that displayed a kinetic sta-
bility of approximately 26 hr with I-Ad, three P1 mutants
displayed increased stability with I-Ad molecules rang-
ing from 63 to 165 hr (Table 1 and Figure 2B). Lower
stability variants showed half-lives of 1 and 0.9 hr, re-
spectively (Table 1 and Figure 2B). The variants summa-
rized in Table 1 provided a range of kinetic stabilities
to study and also highlighted the importance of single
amino-acid interactions with the class II pockets upon
the overall stability of the class II:peptide complex.
Whereas the successful crystallization of I-Ad:HA
(126–138) facilitated the design of variant peptides, the
core binding sequence of LACK (156–173) was notknown. Use of truncated peptides (see Figures S1A and
S1B in the Supplemental Data available with this article
online) indicated the binding core to be residues (163–
171) and suggested the following amino acid register
from P1 to P9: EHPIVVSGS. This register fits with some
of the known binding preferences for I-Ad, particularly
Ile at P4 and Val at P6 (Figure S1C). To derive lower
kinetic stability variants for LACK, we substituted Ala
for Ile at P4 (I166A). This variant sustained T cell stimu-
lation to wt LACK (161–173) (Figure 2C) and displayed
a half-life of only 2 hr, nearly 100-fold less than wt LACK
(Figure 2D). The changes in stability observed with
I166A demonstrated that this residue interacted with
I-Ad pockets as hypothesized and verified this register
for LACK (156–173):I-Ad.
Determination of the register of the HEL (11–25) pep-
tide presented us with unique challenges. Because of
its extremely weak interaction with I-Ad, this peptide
was not expected to possess even the poorly defined
“motif” for I-Ad (Sette et al., 1988). As shown (Figure
S1D), we used functional studies to determine its bind-
ing register with I-Ad. These analyses suggested that the
likely register for the HEL (11–25) peptide with I-Ad was
AMKRHGLDNYRGYSL, with the bold residues indicat-
ing P1, P4, P6, and P9. Higher stability variants of HEL
(11–25) displayed half-lives of 11 or 35 hr, respectively
(Figure 2F).
Implementation of a Peptide Shuttle Vector
for CD4 T Cell Epitopes
To study the relationship between peptide off-rates and
immunogenicity, we required a protein shuttle vector
that could accept heterologous peptide inserts. To pre-
vent self-reactive T cells from interfering with re-
Immunity
32Figure 2. Identifying Kinetic Stability Variants of HA (126–138), LACK (156–173), and HEL (11–25)
(A, C, and E) Candidate peptide variants were identified by in vitro stimulation of 5 × 104 specific hybridomas with soluble peptide presented
by 4 × 104 I-Ad-expressing L cells. IL-2 production by HA TS2 (A), LMR 7.5 (C), and HEL 25 (E) hybridomas in response to 667 nM (A and E)
or 300 nM (C) peptide was measured as described in the Experimental Procedures. Data are representative of three independent experiments.
(B, D, and F) Dissociation of peptides from I-Ad was found to fit a single exponential curve with a square correlation coefficient, r2 > 0.99,
from which t1/2 could be determined. Data are representative of at least two independent experiments.sponses to inserted epitopes, we used a vector that a
Ahad no murine homolog. The protein vector chosen,
MalE, encodes a subunit of the E. coli maltose binding
pprotein and can accept inserts of greater than twenty
amino acids (Martineau et al., 1992). The use of the w
bsame protein vector for all of the test peptides has the
advantage of providing the same set of competing pep- i
btides, thus controlling for T cell competition events and
allowing us to track responses to these MalE peptides M
Din all the immunization studies. To take advantage of
this, we characterized the immunodominant epitopes i
twithin MalE and found that in BALB/c mice, MalE (69–
82) was consistently dominant, whereas MalE (103–118) nnd MalE (269–285) were subdominant (S.A.J. and
.J.S., unpublished data).
In an effort to equalize three-dimensional context and
rotease sensitivity among the variant or wt peptides,
e chose a single insertion site for the peptides. Also,
ecause insertions that perturb structure diminish affin-
ty to maltose, the purification strategy chosen was
ased on the functional association of peptide-inserted
alE with crosslinked amylose (Martineau et al., 1992).
NA encoding each peptide of interest was inserted
nto amino acid 133 flanked by five to seven carboxyl-
erminal and amino-terminal residues (Figure 3A) of the
ative peptide to preserve potential T cell receptor
Kinetic Stability Controls Immunodominance
33Figure 3. Construction of Hybrid MalE Used
to Incorporate Antigenic Peptides
(A) DNA encoding antigenic peptides with
flanking residues was inserted in-frame into
MalE at amino acid 133 via BamHI ligation.
(B) MalE:HA, (C) MalE:LACK, or (D) MalE:HEL
purified from sequenced clones was tested
for the ability to activate 5 × 104 peptide-
specific hybridomas in vitro by using 5 × 105
BALB/c spleen as APCs. As a measure of T
cell stimulation, IL-2 production was assayed
by CTLL proliferation with an MTT assay.(TCR) contacts (Arnold et al., 2002). With insertion of
the HA (126–138), LACK (156–173), and HEL (11–15)
peptide epitopes into MalE, the respective T cell hy-
bridomas gained reactivity (Figures 3B–3D), indicating
that the inserted peptides were liberated during pro-
cessing of the protein.
Immunogenicity of Peptide Variants In Vivo
To examine the immunogenicity of the heterologous
test peptide variants within MalE, IL-2 ELISPOT assays
were used to quantify the number of CD4 T cells speci-
fically responding to peptides ex vivo. To compare data
collected from independent experiments, we normal-
ized spot counts for all the tested peptides relative to
the total number of T cells that responded in vitro to
the original MalE:insert protein used for immunization.
Data shown represent the average of at least three in-
dependent experiments. We found HA (126–138) to be
cryptic in BALB/c mice when inserted into MalE. Very
few T cells specific for HA (126–138) could be detected
in immunized mice. The occasional single spot above
background corresponded to less than one in 500,000
lymph node cells. Thus, a kinetic stability of 26 hr is
insufficient for recognition of HA (126–138). We next in-
vestigated whether variants of HA (126–138), which dis-played increased kinetic stability, could overcome the
crypticity of wt HA (126–138). BALB/c mice were immu-
nized with the high-stability variant HA T128V (t1/2 = 86
hr) encoded in MalE (MalE:T128V). Strikingly, this assay
revealed that the higher-stability HA peptide success-
fully recruited T cells in vivo. Approximately 20% of the
specific response was dedicated to the HA variant pep-
tide, similar to the magnitude of MalE (103–118)- and
MalE (269–285)- specific responses (Figure 4A), demon-
strating that a half-life of 86 hr is sufficient for recogni-
tion of HA (126–138) in vivo. We also found that the two
other high-stability variants of HA gained immunoge-
nicity. The number of CD4 T cells responding to HA
T128M (t1/2 = 165 hr) was also equivalent to the two
subdominant backbone MalE peptides previously iden-
tified. When inserted into MalE, the HA:T128Q variant
that displayed a kinetic stability of 63 hr was more im-
munogenic than the wt peptide, although not as potent
as the higher-stability variant. In contrast, when low-
stability variants of HA were inserted into MalE and
tested for immunogenicity, these peptides were not im-
munogenic. Responses to HA V131A (P4) and T128G
(P1), both of which displayed quite low kinetic stability
interactions with I-Ad (t1/2 of 3 and 1 hr, respectively;
Figure 4B), represented less than 4% of the overall re-
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Figure 4. Kinetic Stability of Peptide:MHC Complexes Controls In L
pVivo Recognition of CD4 T Cell Epitopes
TGroups of two mice (A, B, and C, BALB/c; B, B10.D2) were immu-
onized in the footpad with 20 g/ml (A and B) or 200 g/ml (C) of
the indicated protein emulsified in 50 l PBS:CFA. The number of
IL-2-producing cells at day 10 was determined by 16 hr in vitro
stimulation of unpurified (A and B) or CD4 purified (C) cells with
syngeneic spleen cells and 20 g/ml (A and B) or 200 g/ml (C) t
MalE protein or 5 M peptide antigen by using IL-2 ELISPOT as- i
says. Data represent the mean counts of two separate cell dilutions p
([A] and [B], 1 × 106 and 5 × 105; [C], 5 × 105 and 2.5 × 105) of mbtained with the MalE peptide shuttle protein. The
riplicate wells normalized as a percent of the response against the
mmunizing protein with background spot counts subtracted. Data
resented represent the mean of at least three independent experi-
ents ± SD.ponse (Figure 4A). Finally, we were able to reverse the
attern of immunodominance gained with the HA
128V peptide. A new variant of T128V described
bove was designed to reduce its stability with I-Ad
olecules. By substituting the P9 residue Ser in HA
ith the closely related Thr residue, the kinetic stability
f HA T128V was reduced from 85 hr to 9 hr (Figure 2B).
s shown in Figure 4A, the T128V, S136T variant of HA
ecame cryptic in the CD4 T cell response when in-
erted into MalE. These data further support the idea
hat the immunogenicity of a peptide can be up or
own regulated solely by changing its kinetic stability
ith class II molecules.
We next investigated recognition of the LACK (156–
73) peptide epitope inserted within MalE (MalE:LACK)
s a protein immunogen for H-2d mice. The results of
his experiment demonstrated that LACK (156–173)-
pecific T cells dominated the in vivo response, in fact
urpassing the response to the MalE epitopes (Figure
B). Over one in 16,000 lymph-node cells recognized
ACK (156–173), which corresponded to an average of
7% of the total response to MalE:LACK protein in
10.D2 mice and 44% in BALB/c mice. These results
how that the kinetically stable LACK (156–173) epitope
s immunodominant within MalE. To determine whether
educing the kinetic stability of LACK with I-Ad would
e sufficient to extinguish its immunodominance, the
166A variant of LACK (156–173) (t1/2 = 2 hr) was tested
Figure 2D). The results of this experiment (Figure 4B)
howed a lack of priming toward the low stability
ACK:I166A epitope when inserted within MalE. T cells
rom MalE:I166A-immunized mice did not respond de-
ectably to either the I166A variant peptide or the wt
ACK (156–173) peptide. The number of lymph node
ells specifically responding to LACK dropped precipi-
ously, corresponding to fewer than one in 500,000
ymph-node cells. Responses against the MalE protein
nd backbone MalE peptides were clearly evident, indi-
ating the MalE:I166A variant protein was effectively
rocessed by APCs and that other MalE peptides
ithin it were successfully presented. These results
uggest that by reducing the kinetic stability of the
inding of LACK to the I-Ad molecule, we have suc-
essfully eliminated the in vivo response to a normally
mmunodominant peptide.
To address whether the modulation of immunodomi-
ance with the MalE shuttle vector is unique to this ex-
ression system, we mutated the LACK (156–173) epi-
ope in its normal molecular context. Recombinant
ACK protein containing the wt peptide sequence or
ith a mutation at residue I166A, described above, was
sed to immunize BALB/c mice. T cells from the drain-
ng lymph node were tested for reactivity with the intact
ACK protein, the wt LACK peptide, the I166A variant
eptide, or PPD as an immunization control (Figure 5).
he results of this experiment confirmed the results
Kinetic Stability Controls Immunodominance
35Figure 5. Kinetic Stability of LACK (156–173) with I-Ad Controls the
Immunogenicity within Native LACK Protein
Groups of two BALB/c mice were immunized in the footpad with
200 g/mL of purified LACK protein (upper) or purified LACK:I166A
protein (lower) emulsified in 50 L of PBS:CFA. The number of IL-
2-producing cells at day 10 was determined by 16 hr in vitro stimu-
lation of CD4-purified cells with syngeneic spleen cells and a range
of protein or peptide concentrations. Shown are: LACK and LACK
I66A protein, 200 g/mL and 8 g/mL; LACK and LACK:I166A pep-
tide, 50 M and 2 M; PPD, 5 g/mL and 1 g/mL. Spots were
quantified by using triplicate wells of IL-2 ELISPOT assays with
background subtracted and are representative of two indepen-
dent experiments.strongly immunodominant LACK (156–173) peptide can
be rendered cryptic by simply reducing the stability of
its interaction with I-Ad. Our results also show that the
loss in immunodominance is not due to loss of T cell
reactivity, because the LACK:I166A variant peptide ef-
fectively stimulates the T cells that were primed against
the wt protein.
To extend our studies to a third antigen, the cryptic
HEL peptide (Moudgil et al., 1997) and its variants were
analyzed for immunogenicity. When incorporated into
the MalE protein vector, the failure in immunogenicity of
the HEL (11–25) peptide persisted (Figure 4C). A higher
stability variant (t1/2 = 11 hr; Figure 2F) with changes at
P1 and P9 (R14Q and G22S, respectively) was incorpo-
rated into MalE and tested in vivo, and it remained non-
immunogenic. However, when an HEL peptide variant
with changes at P1, P6, and P9 (R14Q, N19A, and
G22S, respectively; t1/2 = 35 hr; Figure 2F) was inserted
into MalE, we observed a significant gain in immunoge-
nicity, suggesting a peptide ordinarily sequestered from
an immune response can become immunogenic by en-hancing the stability of its interaction with class II mole-
cules.
Kinetic Stability Variants Retain
Crossreactivity In Vivo
The possibility existed that we had created novel TCR
contact profiles with the designed kinetic stability vari-
ants that either enhanced or abrogated T cell recogni-
tion compared to wt peptides. To evaluate this issue
comprehensively, mice were immunized with wt or vari-
ant peptides and T cells were tested for recognition of
both wt and variant peptide (Figure S2). We observed
no change in the number of lymph-node cells that rec-
ognized the wt HA (126–138) or T128V variant peptide
within each immunization condition (Figure S2A). Addi-
tionally, when tested for crossreactivity, we found no
significant difference in the number of lymph node cells
recognizing the wt or low-stability LACK (156–173) vari-
ants (Figure S2B). The vigorous responses to both HA
(126–138) and LACK:I166A (156–173) as peptide immu-
nogens also demonstrate that a lack of T cell precur-
sors is not the explanation for the observed crypticity
of the epitopes within MalE. The HEL variants were not
as straightforward in their phenotype. When mice were
immunized with the HEL:R14Q, N19A, G22S peptide, a
significant portion of the T cells elicited were nonre-
active with the wt HEL peptide (Figure S2C), suggesting
that this peptide variant offers additional epitopic resi-
dues and can thus recruit T cells with additional speci-
ficities. To address the relative contribution of epitopic
changes versus kinetic stability in the immunogenicity
of the HEL peptides, mice were immunized with MalE
containing either the wt HEL or R14Q, N19A, G22S pep-
tide inserts. Although some of the gain in reactivity is
attributable to recruitment of T cells of new specificity,
a significant portion is due solely to the increased sta-
bility of the R14Q, N19A, G22S peptide complexed with
I-Ad (Figure S2D).
The Normally Cryptic OVA (327–339) Epitope
Recognized by the 3DO11.10 TCR Can
Be Made Immunodominant
To provide another example of a cryptic epitope that
can gain immunodominance by simply changing its ki-
netic stability with I-Ad, we studied one of the peptide
registers contained within the prototypic I-Ad-restricted
peptide OVA (323–339) (Jenkins et al., 2001; Sette et al.,
1988). Several studies (McFarland et al., 1999b; Robert-
son et al., 2000) have shown that this long peptide con-
tains several alternative registers, including the most
amino-terminal segment that was cocrystallized with
I-Ad (Scott et al., 1998). The register of OVA (323–339)
peptide recognized by the 3DO11.10 T cell is the most
carboxyterminal segment, with residue 329 constituting
the P1 position (Robertson et al., 2000; Buus et al.,
1987), which we confirmed through the use of the trun-
cated peptide 327–339 (not shown). When the stability
of this peptide with I-Ad was measured (Figure 6A), we
found, surprisingly, that it displayed a very low kinetic
stability of 0.3 hr. To test whether this low stability pep-
tide was cryptic, we immunized mice with the OVA pro-
tein and tested for T cells that recognize OVA (327–339).
Less than 1% of T cells raised against OVA recognize
Immunity
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Groups of two BALB/c mice were immunized in the footpad with (A) 200 g/mL OVA protein, (B) 200 g/mL of the indicated MalE protein, or
(D and E) 5 nmol of the indicated peptide emulsified in 50 L PBS:CFA. The number of IL-2-producing cells at day 10 was determined by 16
hr in vitro stimulation of CD4-purified cells with syngeneic spleen cells and (A) 200 g/mL protein or 12.5 M peptide, (B) 200 g/mL protein
or 5 M peptide, or (D and E) the indicated amount of peptide and quantified with IL-2 ELISPOT assays with background subtracted. The
data presented represent the mean of two independent experiments ± SD.
(A and B) Data represent the mean counts of two separate cell dilutions (2.5 × 105 and 1.25 × 105) of triplicate wells normalized as indicated.
(C) Dissociation of peptides from I-Ad was found to fit a single exponential curve with a square correlation coefficient, r2 > 0.99, from
which t1/2 could be determined. Asterix (*) indicates no detectable stimulation above background. Data are representative of at least two
independent experiments.OVA (327–339) (Figure 6B), indicating that it is cryptic. v
cA variant with substitutions at P4 and P6 (A332I and
I334V, respectively) that was anticipated to improve d
lbinding to I-Ad, was recognized by the 3DO11.10 T cell
hybridoma (not shown) and showed a greatly enhanced g
cstability with I-Ad, with a t1/2 greater than 80 hr (Figure
6B). Additionally, T cells raised against the P4/P6 vari- I
ant crossreacted back onto the wt OVA peptide (Fig-
ures 6C and 6D). To evaluate dominance of the higher D
stability peptide, both the wt and variant OVA peptides
were incorporated into MalE and tested for immunoge- W
nicity in BALB/c mice (Figure 6E). These studies re-ealed that improved P4 and P6 pocket interactions
onverted the cryptic OVA peptide into an immuno-
ominant peptide. Collectively, our results suggest, un-
ike the situation with the HEL (11–25) peptide, that the
ain in immunogenicity of the OVA peptide can be ac-
ounted for by its more stable interaction with the class
I-presenting molecule.
iscussion
e initiated these experiments to determine whether
the magnitude of CD4 T cell priming to a given peptide
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37in a complex antigen is due to an intrinsic property of
the class II:peptide complex. After investigating both
peptide competition and peptide dissociation, we found
that the kinetic stability of class II:peptide complexes
correlated dramatically with the epitopes’ observed im-
munodominance. These findings agree with studies of
the murine T cell response to human cartilage glycopro-
tein 39 (Hall et al., 2002). Dissociation assays provide a
more simplified measure of affinity because competi-
tion assays more completely reflect the mechanistically
complicated process of peptide binding to class II
molecules (Beeson and McConnell, 1994, 1995; Joshi
et al., 2000; Kasson et al., 2000; Natarajan et al., 1999;
Rabinowitz et al., 1998; Sadegh-Nasseri and McCon-
nell, 1989) and are highly subject to experimental vari-
ability (Table S1). To investigate a causative relationship
between kinetic stability of a peptide with the class II
molecule and its in vivo recognition by T cells, kinetic
stability variants of four independent test peptides (HA
[126–138], LACK [161–173], HEL [11–25], and OVA
[327–339]) were incorporated into MalE. These experi-
ments revealed that immunodominance can be con-
ferred by increasing the kinetic stability of a given peptide
with MHC class II and conversely can be eliminated by
decreasing the kinetic stability of a peptide with MHC
class II molecules.
The dramatic linkage between kinetic stability and
in vivo recognition demonstrated here raises several
critical questions. Most importantly, at what stage dur-
ing presentation does the kinetic stability of a class
II:peptide complex physiologically influence the rec-
ognition and expansion of specific T cells? Peptide epi-
topes must overcome at least three distinct hurdles for
recognition by specific T cells in vivo: (1) loading onto
class II in endocytic compartments and export to the
surface of antigen-presenting cells; (2) survival of class
II:peptide molecules during the transit of antigen-bear-
ing dendritic cells to the draining lymph node; and (3)
sustained TCR signaling once contact between CD4 T
cells and the antigen-bearing dendritic cells is estab-
lished. The first checkpoint is monitored by the pres-
ence of DM (Nanda and Sant, 2000), which exerts a
critical regulatory role in editing peptides presented by
class II molecules through discrimination among as-
sembled class II peptide complexes within endosomal
compartments of APCs (reviewed in Busch et al., 2000;
Kropshofer et al., 1997; Sant et al., 2005; Vogt et al.,
1999). A mechanism for DM-mediated selection of im-
munodominant epitopes based on kinetic stability is
consistent with evidence that the catalytic effect of DM
on class II:peptide dissociation is determined by the
intrinsic off-rate of the complexes (reviewed in Jensen
et al., 1999; Vogt et al., 1999), although recent data sug-
gest this to be an imperfect correlation (Belmares et al.,
2002). In this model, although dissociation of immuno-
dominant class II:peptide complexes may be promoted
by DM, the high stability of these complexes will lead to
negligible effects during the time frame of endosomal
colocalization with DM. Thus, most immunodominant
complexes persist in the presence of DM and are dis-
played at a high initial density on the surface of prim-
ing APCs.
High kinetic-stability peptides may possess addi-
tional advantages during later events in T cell priming.
Once class II:peptide complexes reach the cell surface,they must persist long enough to survive transit of the
priming dendritic cell from the site of antigen uptake
to the draining lymph nodes (reviewed in Germain and
Jenkins, 2004). Studies by Mellman and colleagues
have shown that uptake of antigen is lost during matu-
ration of DC (Mellman and Steinman, 2001). Therefore,
dendritic cells are essentially pulsed with antigen be-
fore transit to the lymph node, and any peptides that
dissociate from class II molecules are not replenished.
This transit time represents the second kinetic-stability
checkpoint for a class II:peptide complex to survive.
After relocation to lymph nodes, dendritic cells must
maintain surface presentation of class II:peptide com-
plexes in order to recruit antigen-specific T cells and to
engage in sustained interactions, estimated to be 10–
20 hr (Huppa et al., 2003; Lanzavecchia and Sallusto,
2001). Dissociation of class II:peptide complexes dur-
ing T cell-APC interactions might lead to an abortive
activation signal that does not sustain ultimate expan-
sion and differentiation of T cells (Mirshahidi et al.,
2004; Ryan et al., 2004). Finally, kinetically stable com-
plexes may be required to stimulate daughter cells from
early cell divisions. These factors, when combined, may
lead to a significant competitive advantage for T cells
specific for the high-stability complexes.
One question that may arise from our studies is how
closely the off-rates we measure relate to off-rates of
peptides from class II molecules on live APCs in vivo.
We do not expect the measured off-rates here to pre-
cisely mimic dissociation rates in live APCs, although
these values will likely reflect relative kinetic stabilities
in endosomal compartments. We have found reason-
ably good agreement between off-rates in vitro of fluo-
rescently labeled peptide at pH 7.2 with dissociation
rates of peptides from live APCs measured with T cells
(Figure S3).
Our experiments do not discount the influence of
processing upon the selectivity of the in vivo T cell re-
sponse, and we expect that there will likely be excep-
tions to the paradigm we have established here. Endo-
peptidases have been described to either enhance
(Schneider et al., 2000) or destroy (Burster et al., 2004;
Manoury et al., 2002) epitopes available for class II
molecules. A prominent protease cleavage site within
the minimal epitope can prevent an immune response
if these peptides are destroyed before they can bind
and be protected from proteolysis by the class II mole-
cule. Also, antigens that either have a high degree of
tertiary structure or tend to aggregate may sequester
peptides from proteolytic release and, thus, from avail-
ability for binding to class II molecules. Finally, the
requirement for high-stability interactions of a peptide
with the class II molecule for immunodominance in CD4
T cells may be bypassed during responses to antigens
synthesized within the APC or those made by patho-
gens that replicate within the host APC. Continual syn-
thesis of these peptides may obviate the need for high-
stability interactions with class II molecules. This may
explain why HA (126–138), which has a modest kinetic
stability with I-Ad (25–30 hr), was found to be well repre-
sented in the response to influenza virus (Gerhard et
al., 1991). Our own studies of self-antigens recognized
by T cells (Katz et al., 1996) suggest that these are fre-
quently antagonized by DM, consistent with lower-
affinity interactions with class II molecules (Sant et al.,
Immunity
38C2005). Finally, we expect that T cell repertoire asymmet-
Fries would, in some cases, lead to exceptions to the
(close predictive relationship between stability and im-
r
munodominance, which we have found in our studies. c
Class II-restricted presentation of self-antigens or 1
pthose closely related to self in the thymus can skew
athe developing T cell repertoire, selecting out T cells
Hresponsive to immunodominant epitopes. Thus, subse-
uquent antigenic challenge in the periphery would reveal
t
a bias in the T cell response for epitopes with low ap-
parent affinity for class II molecules. Such effects on T T
cell repertoire are supported by a number of papers in T
(the literature (Harrington et al., 1998; Liu et al., 1995;
APhelps et al., 1998; Targoni and Lehmann, 1998; Wong
eet al., 2001). For this reason, we have restricted our
p
studies primarily to exogenous foreign antigens. a
Collectively, the experiments described here show f
that for many antigens, a single biochemical feature of f
ta given peptide within a complex immunogen directly
and quantitatively controls the immunogenicity of that
Ipeptide during the CD4 T cell response. Furthermore,
Bthis parameter—the off-rate of the peptide from the
o
presenting class II molecule—can be profoundly modu- (
lated by single amino-acid changes in the peptide, p
leaving T cell recognition intact. Thus, varying kinetic n
vstability of MHC class II:peptide complexes represents
1a unique and powerful method of tuning in vivo recogni-
ction towards a preferred outcome in CD4 T cell re-
w
sponses. I
MExperimental Procedures
P
gAntibodies and Peptides
IPurified rat anti-mouse IL-2 (JES6-1A12) antibodies and biotiny-
alated rat anti-mouse IL-2 (JES6-5H4) antibodies were obtained
sfrom BD Pharmingen. Synthetic peptides were obtained from com-
cmercial sources or were the generous gifts of C. Beeson (Medical
tUniversity of South Carolina), N. Glaichenhaus (University of Nice),
mand D. Fowell (University of Rochester).
L
LPurification of Soluble I-Ad Proteins
tA chimeric soluble I-Ad protein (sI-Ad) with a small segment of the
(carboxyterminal domains of I-A replaced with I-E sequences was
tused for peptide binding studies. We have shown that the modifi-
Lcations improve dimer stability but do not affect peptide binding
ccharacteristics of class II molecules (Chaves et al., 2005). Transfec-
rtants expressing the PI-linked class II molecules were used as a
ssource of class II molecules, which were obtained from detergent
qlysates of transfectants by antibody affinity chromatography as de-
Pscribed (Chaves et al., 2005).
N
p
aDissociation Experiments
csI-Ad (50 nM final concentration) was mixed with FITC peptide (5
sM final concentration) in McIlvaines buffer pH 5.3 (0.2 M citric
acid, 0.5 M Na2HPO4), 0.2 mM n-dodecyl maltoside, 0.025% NaN3
Sin the presence of protease inhibitors for 1–16 hr at 37ºC. sI-Ad-
SFITC-peptide complexes were separated from free FITC-peptide by
tpassage over a Micro Bio-Spin 30 column, and the complexes were
aincubated at 37ºC and pH 5.3 for increasing lengths of time in the
cpresence of 5 M unlabeled Eα (52–68) peptide to avoid rebinding
of the fluorescinated peptide. At each time point, a sample of the
dissociation mixture was injected into a LC-10AT HPLC (Shimadzu A
Corporation) equipped with a Bio-Sep-SEC-S 3000 column 300 ×
7.8 mm (Phenomenex Inc.) connected to an in-line fluorescence T
Gdetector (RF-10AXL fluorescence detector; Shimadzu Corporation)
as described (Chaves et al., 2005). tompetition Experiments
or competition assays, 20 nM of soluble I-Ad and 1 M FITC-HA
126–138) were used, which we determined to be in the titratable
ange of both components. Unlabeled competitor peptides at final
oncentrations ranging between 0–500 M were mixed and, after
6–20 hr of incubation at 37ºC, the sI-Ad-FITC-HA(126–138) com-
lex was separated from free peptide and quantified as described
bove. Inhibition by competitor peptides was calculated with the
ill equation (Hill, 1910), with the IC50 value as the concentration of
nlabeled competitor peptide required to achieve 50% inhibition of
he labeled peptide binding to class II molecules.
Cell Hybridoma Assays
he LACK-specific hybridoma (4F7) and HA-specific hybridoma
TS2) were created by fusion of peptide-activated LN cells from the
BLE mouse (Reiner et al., 1998) (4F7) or HNT-TCR mouse (Scott
t al., 1994) (TS2) with BW5147 lymphoma cells. T cell assays were
erformed as previously described in overnight cultures (Peterson
nd Sant, 1998), with peptide or protein at the specified dose in a
lat-bottom 96-well dish. IL-2 produced by the T cells was quanti-
ied by using CTL.L and MTT assays as previously described (Pe-
erson and Sant, 1998).
mmunizations
ALB/c or B10.D2 mice were immunized in the footpad with 50 l
f 20 g/ml MalE protein or 5 nmole of peptide emulsified in CFA
Sigma-Aldrich). Ten days later, cells were isolated from draining
opliteal lymph nodes. IL-2 production by the unpurified lymph-
ode cells was measured by ELISPOT assay as described pre-
iously (Wang and Mosmann, 2001) by using DMEM media with
0% fetal calf serum (Katz et al., 1996) instead of RPMI and tripli-
ate wells for each condition. Quantification of IL-2-producing cells
as accomplished with an Immunospot reader series 2A by using
mmunospot software version 2.0 (Cellular Technologies Ltd.).
alE Protein Purification
oly acrylamide gel electrophoresis (PAGE)-purified synthetic oli-
onucleotides encoding the desired peptide were obtained from
ntegrated DNA Technologies (IDT) and resuspended in 10 mM Tris
nd 1 mM EDTA at a concentration of 100 M. Annealed double-
tranded DNA was ligated into the MalE133 vector, and sequenced
lones were transformed into MalE (−/−) ER2507 E. coli. MalE pro-
ein was prepared as described (Martineau et al., 1992) with some
odifications (see Supplemental Data).
ACK Protein Synthesis
ACK cDNA expression vector (Mougneau et al., 1995) was mu-
ated at position 166 via Quikchange site-directed mutagenesis
Stratagene) and confirmed by sequence analysis. Overnight cul-
ures of BL21(DE3λ) bacteria (Novagen) transfected with LACK or
ACK:I166A were inoculated into 500 mL of LB with ampicillin and
hloramphenicol and grown at 37oC until an OD600 of 0.5 was
eached. 0.25 mL of 1 M IPTG was added to induce protein expres-
ion, and bacteria were grown for another 3 hr at 37oC and subse-
uently harvested by centrifugation at 5000 × g for 15 min at 4oC.
ellets were resuspended in 100 mL of 10 mM Imidazole, 50 mM
aHPO4, and 300 mM NaCl (pH 8.0) and sonicated for 1 min. Su-
ernatants were pelleted by centrifugation at 26,000 × g for 25 min
t 4oC. Protein was purified from supernatants via Ni-NTA affinity
olumn and assayed for quantity and purity via sodium dodecyl-
ulfate-PAGE analysis.
upplemental Data
upplemental Data including three figures, one table, Supplemen-
al Experimental Procedures, and Supplemental References are
vailable online with this article at http://www.immunity.com/cgi/
ontent/full/23/1/29/DC1/.
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